Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

The term “progressive pulmonary fibrosis” or “PPF” is generally used to describe progressive lung fibrosis in an individual with an interstitial lung disease (ILD) other than idiopathic ...

The conditions commonly considered as ILDs include various disorders such as idiopathic pulmonary fibrosis (IPF), connective tissue disease-ILD (CTD-ILD), chronic hypersensitivity pneumonitis, and ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

6, 2024 — Exhaled breath contains chemical clues to what's going on inside the body, including diseases like lung ... illnesses like asthma and pulmonary fibrosis just got easier if a new ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Prolonged exposure to silica dust, a common mineral found in materials like kitchen countertops, can lead to silicosis, a ...

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

“These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment ... chronic ...